Glow and Klow blends: the logic behind four repair peptides in one vial, and what is missing
Glow combines GHK-Cu with BPC-157 and TB-500; Klow adds KPV. Each ingredient has its own research history. The blends themselves have none, and that gap deserves a clear explanation.
Glow 70 mg
Klow 80 mg
At a glance
- Glow = GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg. Klow = the same three plus KPV 10 mg.
- Each component has been studied mainly for a different part of tissue repair in laboratory and animal work: matrix building, blood-vessel growth, cell migration and inflammation [1,3,4,5].
- We could find no published study, at any level, of either blend as a combination.
- Only GHK-Cu has controlled human data, and those come from small topical trials [2].
- Mixing peptides raises chemistry questions nobody has answered in print, especially around copper [6,7].
Why put four peptides in one vial?
Combination products are common in medicine, but they normally arrive after each drug has been tested alone and then together. Peptide blends like Glow and Klow follow a different path. They come out of research and wellness communities where "stacking" several repair peptides is a familiar idea, a practice NPR described in 2026 alongside the rise of injected copper peptides [12].
The idea is easy to state. Tissue repair is a relay with several legs: clear inflammation, grow new blood vessels, move cells into the gap, then lay down and organise collagen. Each peptide in these blends has been studied mainly for one of those legs, so combining them looks like covering the whole race. Whether it works that way has never been tested.
The four components, one at a time
| Component | Glow | Klow | Main research focus | Highest evidence |
|---|---|---|---|---|
| GHK-Cu | 50 mg | 50 mg | Collagen, wound repair, skin | Small topical human studies |
| BPC-157 | 10 mg | 10 mg | Gut, tendon, ligament, muscle healing | Animal; human data very limited |
| TB-500 | 10 mg | 10 mg | Cell migration, wound repair | Cell and animal, mostly on full-length thymosin β4; no human data for the fragment |
| KPV | none | 10 mg | Inflammation | Cell and mouse |
GHK-Cu: the matrix builder
GHK-Cu is a naturally occurring copper complex of the tripeptide glycine-histidine-lysine. In cell and animal studies it increases collagen and glycosaminoglycan production and modulates the enzymes that remodel the skin's matrix [1]. It is also the only blend component with human skin data, although a 2026 systematic review describes those trials as small, mostly cosmetic and partly unpublished [2]. By weight, it makes up most of each vial.
BPC-157: the vessel and tendon peptide
BPC-157 is a synthetic 15-amino-acid peptide derived from a stomach protein. A 2018 review by a Croatian research group reports that it was consistently effective across animal models of injury to the oesophagus, stomach and intestine, and that it improves tendon, ligament and bone healing in animals, partly through effects on blood-vessel growth [3]. Human data remain very limited.
TB-500: the cell mover
TB-500 is a short synthetic fragment of thymosin β4, listed by the FDA as the sequence LKKTETQ [8]. The parent protein binds actin, the cell's internal scaffolding, and promotes cell migration, new blood vessels and reduced scarring in wound models [4]. The important caveat: clinical trials in skin, eye and heart repair used full-length thymosin β4, not TB-500 [4]. The FDA states it has found no human exposure data for the fragment [8].
KPV: the inflammation brake (Klow only)
KPV is the tripeptide lysine-proline-valine, the last three amino acids of the hormone α-MSH [5]. In human gut and immune cells, nanomolar KPV inhibited the NF-κB inflammatory pathway, and in two mouse models of colitis, KPV in drinking water reduced inflammation and weight loss [5]. The FDA notes that it has found no human exposure data for KPV [8].
What the research shows about the blends
Nothing yet, and it is worth being precise about what that means.
As far as we can find, there is no published cell, animal or human study of GHK-Cu, BPC-157 and TB-500 given together, with or without KPV.
Without such studies, nobody knows whether the components add up, cancel out, or simply coexist. The effects of each peptide were measured alone, often at concentrations or in tissues that have nothing to do with the others. A combination can behave differently from the sum of its parts, which is why medicines that combine active ingredients are normally tested as combinations.
The mass ratio also hides a molecular one. GHK-Cu is small (about 403 g/mol) and BPC-157 is large (1,419.5 g/mol), so the 50 mg to 10 mg split means roughly 18 GHK-Cu molecules for every BPC-157 molecule.
What we don't know yet
- Stability of the mixture. Each peptide has its own sensitivity to pH, oxidation and enzymes. We found no published stability data for these four peptides lyophilised or dissolved together.
- Copper on the move. GHK does not lock copper away permanently. In solution, the copper complex can bind a fourth partner such as glycine or histidine, and copper swaps between GHK molecules quickly [6]. Glutathione can reduce GHK's copper and help release it [7]. Whether BPC-157, TB-500 or KPV act as partners in this way, or whether freed copper speeds their oxidation, has not been studied.
- Testing. Verifying a four-peptide vial means separating and quantifying each component, which is harder than testing a single peptide.
- Safety in combination. FDA reviewers have flagged immunogenicity and limited safety data for several of these peptides individually [8]. No data exist on combined exposure.
Regulatory status
None of the four components is an approved medicine. In the US, the FDA's safety page lists BPC-157, injectable GHK-Cu, KPV and TB-500 among substances whose compounding nominations were withdrawn, each with stated safety-data concerns (page current as of April 2026) [8]. In July 2026, the FDA's Pharmacy Compounding Advisory Committee voted, against FDA staff advice, to recommend BPC-157, KPV, TB-500 and three other peptides for the compounding list; the vote is not binding [11]. The FDA plans to consult the committee on GHK-Cu by February 2027 [9].
For sport, the 2026 WADA Prohibited List names BPC-157 under S0 (non-approved substances) and thymosin β4 derivatives such as TB-500 under S2 [10]. Any blend containing them is therefore prohibited at all times.
In the lab: handling and storage
Glow and Klow are supplied as lyophilised powders, typically stored at −20 °C long term and at 2–8 °C for short periods, protected from light and moisture. The blue tint comes from the GHK-Cu copper complex. Because no stability data exist for these mixtures once dissolved, common practice is to reconstitute only what is needed, keep solutions cold and avoid repeated freeze-thaw cycles. Each lot comes with a certificate of analysis from an independent laboratory. Synthos supplies Glow and Klow for research use.
FAQ
What is the difference between Glow and Klow?
Glow contains GHK-Cu, BPC-157 and TB-500. Klow contains the same three peptides plus 10 mg of KPV, an α-MSH fragment studied for anti-inflammatory effects [5].
Have the Glow or Klow blends been clinically tested?
No. We found no published study of either blend. The research cited for them is research on the individual peptides.
Why is the blend blue?
The colour comes from GHK-Cu, whose copper complex absorbs orange-red light and therefore looks blue [7].
Are Glow and Klow allowed in sport?
No. BPC-157 and TB-500 are both on the 2026 WADA Prohibited List, so blends containing them are prohibited at all times [10].
How Synthos supplies Glow and Klow blends
Every Synthos lot of Glow and Klow blends is tested by an independent laboratory, and the certificate of analysis for that lot comes with your order. Ask your representative to see it before you pay anything.
Further reading elsewhere
Coverage and explainers from other publications, picked and checked by our team.
- NPR · Sep 2026The copper peptide trend has gone from creams to injections — ahead of the science ↗Reports how GHK-Cu is now often stacked with other repair peptides and why researchers say human data are missing.
- ABC News · Jul 2026FDA advisers narrowly vote to add 6 peptides to a drug compounding list. What's next? ↗Explains what the non-binding committee vote on six peptides means and what has to happen before anything changes.
- TIME · Jul 2026An FDA Committee Just Voted in Favor of Peptides—Despite the Agency's Opposition ↗Covers the July 2026 advisory committee votes on BPC-157, KPV, TB-500 and other peptides, and the evidence concerns raised by FDA staff.
- US FDA · Apr 2026Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks ↗The FDA's page listing the safety-data concerns it has raised for BPC-157, injectable GHK-Cu, KPV and TB-500.
- Healthline · Oct 2020Copper Peptides: Benefits for Skin and Hair Care, and How to Use Them ↗A medically reviewed explainer on copper peptides, the main component of both blends, and the limits of the evidence.
References
- Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci. 2018;19(7):1987. PubMed (GHK-Cu effects on collagen, glycosaminoglycans and matrix remodelling)
- Najafi N, Maatouk H, Vardanyan KG, et al. A systematic review of the mechanisms and therapeutic applications of GHK-Cu (glycyl-L-histidyl-L-lysine-copper complex) in topical microneedle delivery: a case for expanded clinical trials. Arch Intern Med Res. 2026;9(3):269-293. PubMed (size and quality of GHK-Cu human evidence)
- Seiwerth S, Rucman R, Turkovic B, et al. BPC 157 and standard angiogenic growth factors. Gastrointestinal tract healing, lessons from tendon, ligament, muscle and bone healing. Curr Pharm Des. 2018;24(18):1972-1989. PubMed (BPC-157 animal healing models)
- Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37-51. PubMed (actin binding, cell migration, wound repair, clinical trials of full-length thymosin β4)
- Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-178. PubMed (KPV origin from α-MSH, NF-κB inhibition in cells, mouse colitis models)
- Hureau C, Eury H, Guillot R, et al. X-ray and solution structures of Cu(II) GHK and Cu(II) DAHK complexes: influence on their redox properties. Chemistry. 2011;17(36):10151-10160. PubMed (ternary complexes with glycine or histidine; fast copper exchange)
- Ufnalska I, Drew SC, Zhukov I, et al. Intermediate Cu(II)-thiolate species in the reduction of Cu(II)GHK by glutathione: a handy chelate for biological Cu(II) reduction. Inorg Chem. 2021;60(23):18048-18057. PubMed (glutathione reduces GHK-bound copper; 606 nm absorption band)
- US Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks (content current as of April 22, 2026). FDA (status and stated safety concerns for BPC-157, GHK-Cu, KPV and TB-500; TB-500 sequence)
- US Food and Drug Administration. Bulk drug substances nominated for use in compounding under section 503A of the FD&C Act (updated May 14, 2026). FDA (planned advisory committee consultation on GHK-Cu)
- World Anti-Doping Agency. The 2026 Prohibited List, in effect from 1 January 2026. WADA (BPC-157 under S0; thymosin β4 derivatives including TB-500 under S2)
- Semuels A. An FDA committee just voted in favor of peptides, despite the agency's opposition. TIME. July 23, 2026. TIME (July 2026 advisory committee votes on BPC-157, KPV, TB-500 and other peptides)
- Stone W. The copper peptide trend has gone from creams to injections, ahead of the science. NPR. September 7, 2026. NPR (stacking of GHK-Cu with other repair peptides)
This article summarises published research for education and laboratory context. It is not medical advice. Synthos products are sold for laboratory research only and are not approved for human use.